Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Rifampin and Clarithromycin on Deflazacort PK in Healthy Subjects
NCT02286635Phase 1Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Nov 2014
- Primary completion
- Dec 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of deflazacort in Duchenne muscular dystrophy (DMD) (2 cohorts), sponsored by PTC Therapeutics, Inc. Primary endpoint: Area Under the Plasma Concentration-Time Curve at Day 10. Started Nov 2014; status: completed.
02
Drugs
deflazacort
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02286635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02286635.